1Szabo A, Schmutz A, Pesian S, et al. Regulation of intestinal vitamin D receptor expression in experimental uraemia:effects of parathyroidectomy and administration of PHT[J].Nephrol Dial Transplant ,1998,13(2):340-349.
2Olmos JM,Martinez J,de Francisco AL,et al .1,25-Dihydroxyvitamin D3 receptors in peripheral blood monoclear cells from patients with renal insufficiency[J].Methods Find Exp Clin Pharmacol,1998,20(8):699-707.
3Patel SR, Ke HQ, Vanholder R, et al. Inhibition of calcitriol receptor binding to vitamin D response elements by uremic toxins [J].J Clin Invest,1995,96(1) :50- 59.
4Brown AJ, Ritter CS, Finch JL, et al. Decreased calcium- sensing receptor expression in hyperplastic parathyroid glands of uremic rats:role of dietary phospate[J].Kidney Int,1999,55(4): 1284 - 1292.
5Malluche HH, Mawad H. Management of hyperphosphataemia of chronic kidney disease:lessons from1170- 1175.
6Ramsdell R.Renagel:a new and different phosphate binder[J].ANNA J,1999,26(3):346-347.
7Hervas JG, Prados D, CetemS. Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients:A comparison with calcium acetate[J].Kidney Int Suppl,2003,(85):69-72.
8Schomig M, Ritz E. Management of disturbed calcium metabolism in uraemic patient:1.Use of vitamin D metabolites [J].Nephrol Dial Transplant,2000,15(Suppl 5):18 - 24.
9Frazao JM, Chesney RW, Cobum JW.Intermittent oral lalphahydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients ,lalphaD2 Study Group[J].Nephrol Dial Transplant,1998,13(Suppl 3):68-72.
10Halstead LR, Weinstein RS, Cheng SL, et al. Comparison of 22-oxacalcitriol and 1,25-(OH)2D3 on bone metaboism in young X-linked hypophosphatemic male mice [J].Am J Physiol,1996,270(1Pt 1 ) : E141 - E147.
5Block GA, Hulbert Shearon TE, Levin NW et al . Association of serum phosphorus and calcium - phosphorus product with mortality risk in chronic hemodialysis patients: a national study.Am J Kidney Dis,1998,31(66):607.
6Levin NW, Hulberg shearron TE, Straderman RL et al . Which causes of death are related to hyperphosphatemia in hemodinlysis patients. J Am Soc Nephrol, 1998,9: 217.
7Lopez- Merchero R, Miguel A, Garcia Ramon R et al . Importance of residual renal function in continuous ambulatory peritoneal dialysis: its influence on different parameters of renal replacement treatment Nephron, 1999,83 : 219.
8Young EW, Albert JM, Satayathum S et al . Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. Kidney Int, 2005,67: 1179.
9Brandi L, Melsen PK, Bro S et al . Long - term effects of intermittent oral alphacalcidol, calcium carbonate and low- calcium dialysis( 1.25 mmol/1) on secondary phperpamthyroidism in patients on CAPD. J Inter Med, 1998,244:121.
10Sanchez C, Lopez Barea F, Sanchez Cabezudo J et al . Low vs standard calcium dialysate in peritoneal dialysis: differences in treatment, biochemistry and bone histomorphometry. A randomized multicentre study. Niphrol Dial Trans, 2004, 19.1587.
